

DECLARATION (37 CFR §1.63) AND POWER OF ATTORNEY

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name, and

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled Novel G Protein-Coupled Receptors, Docket No. 00196.US1 the specification of which

☒ is attached hereto.

☐ was filed on _____ as Application Serial No. _____ and was amended on _____.

☐ was filed on _____ as PCT International Application No. PCT/US _____ and was amended under PCT Article 19 on _____, if applicable.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with 37 CFR §1.56(a).

I hereby claim the benefit under 35 USC §119(e) of any United States provisional application(s) listed below:

<u>Application Serial No.</u>	<u>Filing Date (Month/Day/Year)</u>
60/195,150	4/6/00
60/195,099	4/6/01
60/195,151	4/6/00
60/195,148	4/6/00
60/195,093	4/6/00
60/195,098	4/6/00
60/230,149	9/5/00

I hereby claim foreign priority benefits under 35 USC §119(a)-(d), or §365(b), of any foreign application(s) for patent or inventor's certificate or §365(a) of any PCT International Application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application for patent or inventor's certificate or any PCT International Application(s) designating at least one country other than the United States of America filed by me on the

same subject matter having a filing date before that of the application on which priority is claimed:

Application <u>Serial No.</u>	<u>Country</u>	Filing Date (<u>Day/Month/Year</u>)	Priority Claimed (<u>Yes/No</u>)
----------------------------------	----------------	--	---------------------------------------

I hereby claim the benefit under 35 USC §120, of any United States application(s) or PCT International Application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application(s) in the manner provided by the first paragraph of 35 USC §112, I acknowledge the duty to disclose material information as defined in 37 CFR §1.56(a), which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Application <u>Serial No.</u>	<u>Filing Date</u>	Status (Patented, <u>Pending Abandoned</u>)
----------------------------------	--------------------	---

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

I hereby appoint Mark DeLuca (Registration No. 33,229), Gwilym J. O. Attwell (Registration No.: 45,449) Carl W. Battle (Registration No. 30,731), James D. Darnley, Jr. (Registration No. 33,673), Bruce Stein (Registration No. 27,231), Thomas A. Wootton (Registration No. 35,004), Lucy X. Yang (Registration No. 40,259), Andrew M. Solomon (Registration No. 32,175), Edward F. Rehberg (Registration No. 34,703), Ellen Park (Registration No. 34,055), and Bruce A. Pokras (Registration No. 32,748), all registered to practice before the Patent and Trademark Office as my attorneys or agents with full power of substitution and revocation to prosecute this application and all divisions and continuations thereof and to transact all business in the Patent and Trademark Office connected therewith and request that all correspondence and telephone communications be directed to the following person(s) at the mailing address and telephone number hereafter given:



Name :Gwilym J. O. Attwell
Registration No. : 45,449
Address :One Liberty Place- 46 Floor
Philadelphia, PA 19103
Telephone No. :215-568-3100
Telefax No. :215-568-3439

Inventor's Signature _____ Dated _____

Full name of sole or first inventor: Gabriel Vogeli
Residence: 2576 9th Avenue West
Seattle, Washington, 98119
Citizenship: United States of America
Post Office Address:

Inventor's Signature _____ Dated _____

Full name of second joint inventor:
Residence: _____ Citizenship: _____
Post Office Address: _____

Inventor's Signature _____ Dated _____

Full name of third joint inventor:
Residence: _____ Citizenship: _____
Post Office Address: _____

DOCKET NO.: 00196.US1

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Gabriel Vogeli

Serial No.: Not yet assigned

Group Art Unit: Not yet assigned

Filing Date: Herewith

Examiner: Not yet assigned

For: Novel G Protein-Coupled Receptors

BOX SEQUENCE

Assistant Commissioner for Patents

Washington DC 20231


STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE
WITH 37 CFR §§ 1.821 THROUGH 1.825

- ☒ I hereby state, in accordance with the requirements of 37 C.F.R. §1.821(f), that the contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR §1.821(c) and (e), respectively are the same.
- ☐ I hereby state that the submission filed in accordance with 37 CFR §1.821(g) does not include new matter.
- ☐ I hereby state that the submission filed in accordance with 37 CFR §1.821(h) does not include new matter or go beyond the disclosure in the international application as filed.
- ☐ I hereby state that the amendments, made in accordance with 37 CFR §1.825(a), included in the substitute sheet(s) of the Sequence Listing are supported in the application, as filed, at pages _____. I hereby state that the substitute sheet(s) of the Sequence Listing does (do) not include new matter.
- ☐ I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 CFR §1.825(b), is the same as the amended Sequence Listing.



I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 CFR §1.825(d), contains identical data to that originally filed.

Date: April 6, 2001



Gwilym J. O. Attwell

Registration No. 45,449

Woodcock Washburn Kurtz
Mackiewicz & Norris LLP
One Liberty Place - 46th Floor
Philadelphia PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439

© 1997 WWKMN

109040-4492260